Cabergoline
Cabergoline is a prescription medication in 0.5 mg oral tablet form, classified as an ergot derivative and ergoline. It's used to treat conditions like hyperprolactinemia and Parkinson's disease. Manufactured by Amneal Pharmaceuticals NY LLC and SKG Pharma Inc. under ANDA218618, with NDC 83085-003, marketed since July 2024. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Cabergoline is a prescription medication in 0.5 mg oral tablet form, classified as an ergot derivative and ergoline. It's used to treat conditions like hyperprolactinemia and Parkinson's disease. Manufactured by Amneal Pharmaceuticals NY LLC and SKG Pharma Inc. under ANDA218618, with NDC 83085-003, marketed since July 2024. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Cabergoline",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Cabergoline — ANDA 204735 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204735"
}
]
|
| identifier | ANDA204735 |
| issued | 2016-09-16 |
| keyword |
[
"drug-manufacturers",
"drug-safety",
"fda",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Cabergoline |
